Compare FEIM & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | RCKT |
|---|---|---|
| Founded | 1961 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 401.6M |
| IPO Year | 1994 | N/A |
| Metric | FEIM | RCKT |
|---|---|---|
| Price | $61.76 | $3.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $51.50 | $29.73 |
| AVG Volume (30 Days) | 161.9K | ★ 2.8M |
| Earning Date | 03-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | $64.28 |
| P/E Ratio | $152.66 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $18.70 | $2.40 |
| 52 Week High | $80.00 | $5.45 |
| Indicator | FEIM | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 56.19 |
| Support Level | $48.25 | $2.96 |
| Resistance Level | $78.04 | $3.52 |
| Average True Range (ATR) | 6.29 | 0.21 |
| MACD | -1.64 | 0.08 |
| Stochastic Oscillator | 6.80 | 69.55 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.